Table 3. Univariable and multivariable logistic regression of predictors for major pathologic response.

Variables	Univariable			Multivariable
	HR (95% CI)	P value		OR (95% CI)	P value
Patients classified as CR/PR
Age		0.173
≤70 years	ref.
>70 years	0.39 (0.10–1.52)
Gender		0.338
Female	ref.
Male	2.17 (0.45–10.53)
Histology subtype		0.678
LUSQ	ref.
Non-LUSQ	0.81 (0.29–2.22)
cT stage at presentation		0.495			0.171
T1–T21	ref.			ref.
T3	0.74 (0.21–2.62)			0.43 (0.10–1.85)
T4	0.51 (0.16–1.57)			0.27 (0.07–1.06)
cN stage at presentation		0.688
N0	ref.
N1	0.83 (0.08–8.24)
N2	1.81 (0.23–14.12)
N3	1.50 (0.15–15.46)
Treatment cycle		0.095			0.045
2 cycles	ref.			ref.
3 cycles	3.14 (0.90–11.03)			4.78 (1.17–19.55)
4 cycles	3.21 (0.70–14.74)			6.50 (1.12–37.54)
≥5 cycles	0.64 (0.12–3.53)			0.91 (0.15–5.47)
Patients classified as SD/PD2
Histology subtype		0.105			0.105
LUSQ	ref.			ref.
Non-LUSQ	0.33 (0.09–1.26)			0.33 (0.09–1.26)
cT stage at presentation		0.774
T1–T21	ref.
T3	1.43 (0.30–6.88)
T4	1.71 (0.37–7.92)
cN stage at presentation		0.986
N0	ref.
N1	1.00 (0.06–16.0)
N2	0.88 (0.11–7.05)
Treatment cycle		0.662
2 cycles	ref.
3 cycles	0.84 (0.13–5.26)
4 cycles	2.24 (0.45–11.11)
≥5 cycles	0.93 (0.11–7.82)

¹, only three patients classified as PR were staged as T1 and three patients classified as SD/PD were staged as T1. ², only four patents with age >70, and only six patients were female; thus, age group and gender were not selected as the potential factors for adjusting the outcome. LUSQ, Lung squamous cell carcinoma; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; HR, hazard ratio; OR, odds ratio; CI, confidence interval.